XML 40 R27.htm IDEA: XBRL DOCUMENT v3.23.2
BUSINESS SEGMENT INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Summary of Segment Reporting Information by Segment The following table is a summary of segment information for the three and six months ended June 30, 2023 and 2022. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2022 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Net revenues:    
DIS business$2,268 $2,384 $4,527 $4,925 
All other operating segments70 69 142 139 
Total net revenues $2,338 $2,453 $4,669 $5,064 
Operating earnings (loss):    
DIS business$410 $442 $784 $1,004 
All other operating segments10 6 18 13 
General corporate activities(72)(60)(149)(116)
Total operating income348 388 653 901 
Non-operating expense, net(31)(65)(59)(126)
Income before income taxes and equity in earnings of equity method investees317 323 594 775 
Income tax expense(75)(77)(140)(187)
Equity in earnings of equity method investees, net of taxes7 4 12 35 
Net income249 250 466 623 
Less: Net income attributable to noncontrolling interests14 16 29 34 
Net income attributable to Quest Diagnostics$235 $234 $437 $589 
Schedule of Revenues by Major Service by major service for the three and six months ended June 30, 2023 and 2022 were as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Routine clinical testing and other services51 %45 %50 %43 %
COVID-19 testing services2 14 3 19 
Gene-based and esoteric (including advanced diagnostics) testing services38 32 37 30 
Anatomic pathology testing services6 6 7 5 
All other3 3 3 3 
Net revenues100 %100 %100 %100 %